Vectus Biosystems

Vectus Biosystems EBIT Margin

The EBIT Margin (Operating Margin) of Vectus Biosystems (VBS.AX) as of Nov 5, 2026 is -352.95 %. In the previous year, EBIT Margin (Operating Margin) was -199.41 % — a change of 77.00% (lower).

EBIT Margin

-352.95 %

YoY

77.00%

Last updated:

EBIT Margin (Operating Margin) of Vectus Biosystems is 2025 -352.95 % . EBIT Margin (Operating Margin) of Vectus Biosystems was 2024 -199.41 % . It decreases by 77.00% lower compared to the previous year.

Vectus Biosystems's operating (EBIT) margin stands at -352.9%, up from -2,068,543.8% several years earlier.

The Vectus Biosystems EBIT Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT Margin
Date
EBIT Margin
Jan 1, 2018
-218,653.04 AUD
Jan 1, 2019
-1.08 M AUD
Jan 1, 2020
-5,203.31 AUD
Jan 1, 2021
-2.07 M AUD
Jan 1, 2022
-253.85 AUD
Jan 1, 2023
-238.92 AUD
Jan 1, 2024
-199.41 AUD
Jan 1, 2025
-352.95 AUD
The Vectus Biosystems EBIT Margin history
YEAREBIT MarginYoY
-352.95 %+77.00%
-199.41 %-16.54%
-238.92 %-5.88%
-253.85 %-99.99%
-2.07 M %+39,654.40%
-5,203.31 %-99.52%
-1.08 M %+393.37%
-218,653.04 %+2,139.88%
-9,761.81 %+82.17%
-5,358.54 %-93.43%
-81,532.50 %+48,058.96%
-169.30 %+8,771.82%
-1.91 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Vectus Biosystems Stock analysis

What does Vectus Biosystems do? Vectus Biosystems Ltd. generates revenue through the development and commercialization of pharmaceutical products targeting fibrotic diseases and hypertension. The company focuses on VB0004, a compound designed to treat tissue hardening and high blood pressure, alongside candidates for fibrotic liver conditions like NASH and pulmonary fibrosis. Its subsidiary Accugen Pty Limited offers the Accugen platform, which provides qPCR reagents and software for accurate DNA and RNA quantification in laboratory testing. The primary buyers of these products are pharmaceutical companies and research institutions seeking advanced drug development tools and therapies for fibrotic disorders. Vectus Biosystems targets the medical research and development sector, specifically addressing unmet needs in fibrotic disease treatment. The Accugen platform serves laboratories requiring efficient molecular analysis tools, with its technology enhancing the speed and precision of qPCR testing. The company’s revenue streams are derived from both therapeutic product development and the sale of diagnostic solutions to biotech firms and academic research entities. The firm’s focus on fibrosis-related treatments, including heart, kidney, and liver diseases, positions it within niche therapeutic segments. Accugen’s reagents and software are sold to laboratories as part of the qPCR workflow, supporting drug discovery processes. Pharmaceutical companies and research organizations are the key segments purchasing Vectus Biosystems’ products for their R&D pipelines and clinical applications. Vectus Biosystems is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Vectus Biosystems stock

EBIT Margin (Operating Margin) of Vectus Biosystems is -352.95 % in 2025.

EBIT Margin (Operating Margin) of Vectus Biosystems changed from -199.41 % to -352.95 %, representing a 77.00% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBIT Margin (Operating Margin) Vectus Biosystems since 2006 – with annual values, charts, and detailed analysis.

EBIT Margin measures operating profitability as a percentage of revenue. It shows how much profit a company makes from operations before interest and taxes.

A 'good' varies by industry and company stage. On Eulerpool, you can compare EBIT Margin (Operating Margin)'s Vectus Biosystems with sector peers and the industry average to assess whether it is attractive.

To evaluate EBIT Margin (Operating Margin)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EBIT Margin (Operating Margin).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Margins — Vectus Biosystems

Gross MarginEBIT MarginEBITDA MarginNet MarginFCF MarginR&D / RevenueTax RatePayout RatioPre-Tax MarginOCF MarginSGA/RevenueOpEx/RevenueReinvestment Rate

All Key Metrics — Vectus Biosystems